265 related articles for article (PubMed ID: 25490969)
1. MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis.
Tembe V; Schramm SJ; Stark MS; Patrick E; Jayaswal V; Tang YH; Barbour A; Hayward NK; Thompson JF; Scolyer RA; Yang YH; Mann GJ
Pigment Cell Melanoma Res; 2015 May; 28(3):254-66. PubMed ID: 25490969
[TBL] [Abstract][Full Text] [Related]
2. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
Larsen AC
Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma.
Caramuta S; Egyházi S; Rodolfo M; Witten D; Hansson J; Larsson C; Lui WO
J Invest Dermatol; 2010 Aug; 130(8):2062-70. PubMed ID: 20357817
[TBL] [Abstract][Full Text] [Related]
4. A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis.
Hanniford D; Zhong J; Koetz L; Gaziel-Sovran A; Lackaye DJ; Shang S; Pavlick A; Shapiro R; Berman R; Darvishian F; Shao Y; Osman I; Hernando E
Clin Cancer Res; 2015 Nov; 21(21):4903-12. PubMed ID: 26089374
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF.
Kim JH; Ahn JH; Lee M
Cancer Res Treat; 2017 Oct; 49(4):947-959. PubMed ID: 28052651
[TBL] [Abstract][Full Text] [Related]
6. Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma.
Jayawardana K; Schramm SJ; Tembe V; Mueller S; Thompson JF; Scolyer RA; Mann GJ; Yang J
J Invest Dermatol; 2016 Jan; 136(1):245-254. PubMed ID: 26763444
[TBL] [Abstract][Full Text] [Related]
7. Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden.
Schramm SJ; Li SS; Jayaswal V; Fung DC; Campain AE; Pang CN; Scolyer RA; Yang YH; Mann GJ; Wilkins MR
Pigment Cell Melanoma Res; 2013 Sep; 26(5):708-22. PubMed ID: 23738911
[TBL] [Abstract][Full Text] [Related]
8. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi.
Sand M; Skrygan M; Sand D; Georgas D; Gambichler T; Hahn SA; Altmeyer P; Bechara FG
Cell Tissue Res; 2013 Jan; 351(1):85-98. PubMed ID: 23111773
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers.
Choi YW; Song YS; Lee H; Yi K; Kim YB; Suh KW; Lee D
Medicine (Baltimore); 2016 Apr; 95(15):e3321. PubMed ID: 27082577
[TBL] [Abstract][Full Text] [Related]
10. Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection.
Picard M; Pham Dang N; D'Incan M; Mansard S; Dechelotte P; Pereira B; Mondie JM; Barthelemy I
Br J Dermatol; 2014 Jul; 171(1):108-14. PubMed ID: 24602025
[TBL] [Abstract][Full Text] [Related]
11. Correlation of chemokine receptor CXCR4 mRNA in primary cutaneous melanoma with established histopathologic prognosticators and the BRAF status.
Mitchell B; Leone D; Feller JK; Bondzie P; Yang S; Park HY; Mahalingam M
Melanoma Res; 2014 Dec; 24(6):621-5. PubMed ID: 25211166
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma.
Fattore L; Campani V; Ruggiero CF; Salvati V; Liguoro D; Scotti L; Botti G; Ascierto PA; Mancini R; De Rosa G; Ciliberto G
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32178301
[TBL] [Abstract][Full Text] [Related]
13. Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells.
Kozar I; Cesi G; Margue C; Philippidou D; Kreis S
Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt B):2980-2992. PubMed ID: 28408301
[TBL] [Abstract][Full Text] [Related]
14. miR-579-3p controls melanoma progression and resistance to target therapy.
Fattore L; Mancini R; Acunzo M; Romano G; Laganà A; Pisanu ME; Malpicci D; Madonna G; Mallardo D; Capone M; Fulciniti F; Mazzucchelli L; Botti G; Croce CM; Ascierto PA; Ciliberto G
Proc Natl Acad Sci U S A; 2016 Aug; 113(34):E5005-13. PubMed ID: 27503895
[TBL] [Abstract][Full Text] [Related]
15. MiRNAs as Potential Prognostic Biomarkers for Metastasis in Thin and Thick Primary Cutaneous Melanomas.
Valentini V; Zelli V; Gaggiano E; Silvestri V; Rizzolo P; Bucalo A; Calvieri S; Grassi S; Frascione P; Donati P; Soda G; Ottini L; Richetta AG
Anticancer Res; 2019 Aug; 39(8):4085-4093. PubMed ID: 31366492
[TBL] [Abstract][Full Text] [Related]
16. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA expression profiling and Notch1 and Notch2 expression in minimal deviation adenocarcinoma of uterine cervix.
Lee H; Kim KR; Cho NH; Hong SR; Jeong H; Kwon SY; Park KH; An HJ; Kim TH; Kim I; Yoon HK; Suh KS; Min KO; Choi HJ; Park JY; Yoo CW; Lee YS; Lee HJ; Lee WS; Park CS; Lee Y;
World J Surg Oncol; 2014 Nov; 12():334. PubMed ID: 25381598
[TBL] [Abstract][Full Text] [Related]
18. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
19. BRAFi induced demethylation of miR-152-5p regulates phenotype switching by targeting TXNIP in cutaneous melanoma.
Li K; Tang M; Tong S; Wang C; Sun Q; Lv M; Sun X; Wang T; Jin S
Apoptosis; 2020 Apr; 25(3-4):179-191. PubMed ID: 32056038
[TBL] [Abstract][Full Text] [Related]
20. Signatures of microRNAs and selected microRNA target genes in human melanoma.
Philippidou D; Schmitt M; Moser D; Margue C; Nazarov PV; Muller A; Vallar L; Nashan D; Behrmann I; Kreis S
Cancer Res; 2010 May; 70(10):4163-73. PubMed ID: 20442294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]